A detailed history of High Vista Strategies LLC transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, High Vista Strategies LLC holds 43,541 shares of MLTX stock, worth $2.27 Million. This represents 0.86% of its overall portfolio holdings.

Number of Shares
43,541
Previous 42,249 3.06%
Holding current value
$2.27 Million
Previous $1.86 Million 18.2%
% of portfolio
0.86%
Previous 0.75%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.15 - $55.4 $51,873 - $71,576
1,292 Added 3.06%
43,541 $2.2 Million
Q2 2024

Aug 14, 2024

SELL
$38.43 - $48.6 $673,293 - $851,472
-17,520 Reduced 29.31%
42,249 $1.86 Million
Q3 2023

Nov 14, 2023

SELL
$48.35 - $61.26 $3.38 Million - $4.29 Million
-69,953 Reduced 53.93%
59,769 $3.41 Million
Q2 2023

Aug 14, 2023

BUY
$19.01 - $51.79 $142,974 - $389,512
7,521 Added 6.15%
129,722 $6.62 Million
Q1 2023

May 15, 2023

BUY
$11.03 - $23.7 $1.35 Million - $2.9 Million
122,201 New
122,201 $2.61 Million

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.93B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track High Vista Strategies LLC Portfolio

Follow High Vista Strategies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Vista Strategies LLC with notifications on news.